secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-06-26T21:15:16+00:00
Accession:  0001104659-26-078327
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA Advisory Committee set for July 29 to review Capricor's Deramiocel BLA; PDUFA date Aug 22
--------------------------------------------------------------------------------

- FDA CTGTAC Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's Deramiocel BLA for Duchenne muscular dystrophy.
- PDUFA target action date remains August 22, 2026; BLA on track.
- BLA supported by Phase 2 HOPE-2, HOPE-2 OLE, and Phase 3 HOPE-3 trials showing statistical significance on primary and secondary endpoints.
- CEO Linda Marbán expressed confidence in the totality of evidence and commitment to urgent needs of DMD community.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/0001104659-26-078327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer